Policy

As payment reform models continue to evolve, practitioners must determine which strategy makes the most sense for their practice. Although the idea behind bundled payments may be worth considering, there are some concerns that this system could causes disruptions in oncology practices.

Patrick Gleason, PharmD, Director of Health Outcomes, Prime Therapeutics, says benefit design trends in specialty pharmacy show that the preferred specialty tier is generally a cost share of around one hundred dollars for a 30-day supply.